ArticleJournal of biomedical semantics2026
Advancing the bioassay ontology through integrated PK/PD and safety pharmacology representation.
Article in Journal of biomedical semantics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The latest release of the BioAssay Ontology (BAO), version 2.8.16, introduces major updates that expand its ability to describe and categorize assays related to pharmacokinetics, pharmacodynamics, and safety pharmacology. These refinements, driven by collaboration with the Semantic Enrichment of Electronic Laboratory Notebook Data project, an industry initiative led by the Pistoia Alliance, address previously identified gaps in ontology coverage. New terms were added for disease models, preclinical study parameters, toxicological measurements, and detailed classifications of pharmacokinetics and pharmacodynamics assays. The update also incorporates biologically relevant target classes, including cytochrome P450 enzymes, solute carrier transporters, and uridine diphosphate-glucuronosyltransferase enzymes. Beyond content expansion, structural improvements include reassignment of terms to more specific and semantically appropriate parent classes, refinement of class dependencies, and enhanced alignment with external ontologies. Anatomical terms were reorganized to follow the Uber Anatomy Ontology hierarchy, and new chemical classes were incorporated to improve compatibility with the Chemical Entities of Biological Interest Ontology. Hundreds of additional axioms were added using existing object properties to capture assay formats, endpoints, detection methods, substrates, design strategies, and biological context. These refinements improve BAO’s semantic precision, interoperability, and reasoning capabilities. As a demonstration of these capabilities, we present a reasoning-based use case in which BAO’s equivalent class axioms enable automated classification of passive cell permeability and active efflux substrate assays. The ontology infers broader mechanistic categories from shared modeled characteristics, grouping transporter-specific and cell-based permeability assays under their mechanistic parents, while excluding assays that do not meet all restrictions. This example demonstrates its ability to support precise, inference-driven retrieval and integration of assay classes. By extending its scope and improving the clarity, consistency, and semantic depth of its classifications, BAO continues to serve as a vital resource for organizing pharmacological data and advancing research in both academic and industrial settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.